Switch theme
Sign up to access all valuation multiples
Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management of postherpetic neuralgia; CAMBIA, for acute treatment of migraine attacks with or without aura in adults of age or older and Zipsor, liquid-filled capsules for relief of mild to moderate pain.
1995
58
LTM Revenue $122M
LTM EBITDA $15.7M
-$0.7M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Assertio Therapeutics has a last 12-month revenue of $122M and a last 12-month EBITDA of $15.7M.
In the most recent fiscal year, Assertio Therapeutics achieved revenue of $125M and an EBITDA of $6.9M.
Assertio Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Assertio Therapeutics valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $152M | $125M | XXX | XXX | XXX |
| Gross Profit | $137M | $125M | XXX | XXX | XXX |
| Gross Margin | 90% | 100% | XXX | XXX | XXX |
| EBITDA | -$223M | $6.9M | XXX | XXX | XXX |
| EBITDA Margin | -147% | 6% | XXX | XXX | XXX |
| Net Profit | $110M | -$332M | XXX | XXX | XXX |
| Net Margin | 72% | -266% | XXX | XXX | XXX |
| Net Debt | $1.9M | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Assertio Therapeutics's stock price is $1.
Assertio Therapeutics has current market cap of $59.6M, and EV of -$0.7M.
See Assertio Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| -$0.7M | $59.6M | XXX | XXX | XXX | XXX | $-0.22 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Assertio Therapeutics has market cap of $59.6M and EV of -$0.7M.
Assertio Therapeutics's trades at -0.0x LTM EV/Revenue multiple, and -0.0x LTM EBITDA.
Analysts estimate Assertio Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Assertio Therapeutics and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | -$0.7M | XXX | XXX | XXX |
| EV/Revenue | -0.0x | XXX | XXX | XXX |
| EV/EBITDA | -0.1x | XXX | XXX | XXX |
| P/E | -2.8x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -0.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpAssertio Therapeutics's NTM/LTM revenue growth is -3%
Assertio Therapeutics's revenue per employee for the last fiscal year averaged $2.2M, while opex per employee averaged $1.8M for the same period.
Over next 12 months, Assertio Therapeutics's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Assertio Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Assertio Therapeutics and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | -18% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 6% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -103% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 3% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $2.2M | XXX | XXX | XXX | XXX |
| Opex per Employee | $1.8M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 3% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 84% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Assertio Therapeutics acquired XXX companies to date.
Last acquisition by Assertio Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . Assertio Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Assertio Therapeutics founded? | Assertio Therapeutics was founded in 1995. |
| Where is Assertio Therapeutics headquartered? | Assertio Therapeutics is headquartered in United States of America. |
| How many employees does Assertio Therapeutics have? | As of today, Assertio Therapeutics has 58 employees. |
| Who is the CEO of Assertio Therapeutics? | Assertio Therapeutics's CEO is Mr. Brendan P. O’Grady. |
| Is Assertio Therapeutics publicy listed? | Yes, Assertio Therapeutics is a public company listed on NAS. |
| What is the stock symbol of Assertio Therapeutics? | Assertio Therapeutics trades under ASRT ticker. |
| When did Assertio Therapeutics go public? | Assertio Therapeutics went public in 1997. |
| Who are competitors of Assertio Therapeutics? | Similar companies to Assertio Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Assertio Therapeutics? | Assertio Therapeutics's current market cap is $59.6M |
| What is the current revenue of Assertio Therapeutics? | Assertio Therapeutics's last 12-month revenue is $122M. |
| What is the current EBITDA of Assertio Therapeutics? | Assertio Therapeutics's last 12-month EBITDA is $15.7M. |
| What is the current EV/Revenue multiple of Assertio Therapeutics? | Current revenue multiple of Assertio Therapeutics is -0.0x. |
| What is the current EV/EBITDA multiple of Assertio Therapeutics? | Current EBITDA multiple of Assertio Therapeutics is -0.0x. |
| What is the current revenue growth of Assertio Therapeutics? | Assertio Therapeutics revenue growth between 2023 and 2024 was -18%. |
| Is Assertio Therapeutics profitable? | Yes, Assertio Therapeutics is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
